Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2010

View Archived Issues

Phase II results encourage further study of perifosine for Waldenstrom's macroglobulinemia

MF59 adjuvant induces antibody repertoire expansion to H5N1 vaccine

Alliance Pharma agrees to buy trade and certain assets of Cambridge Laboratories

FDA grants orphan drug status to Prolastin for alpha-1-antitrypsin deficiency

Phase I data show acceptable safety of BIBF-1120 in gynecological tumors

Glenmark Pharmaceuticals discovers TRPA1 antagonists for the treatment of pain

Israeli scientists disclose novel calcipotriol analogues

Merck KGaA claims novel AMP-activated protein kinase activators

Spanish scientists synthesize novel butyrylcholinesterase inhibitors

Roche and Genentech describe novel PI3K inhibitors for cancer therapy

Resveratrol may protect against vestibular hair cell death

IGF-1 hydrogels improve sensorineural hearing loss

EMEA grants orphan drug designation to AVI BioPharma's AVI-5038 in DMD

FDA approves Paloma Pharmaceutical's IND for phase I trial in AMD

FDA approves Anthera's SPA for phase III trial of A-002 in acute coronary syndrome

GeoVax presents update on development of 2-component HIV-1 vaccine

Resverlogix completes enrollment in phase II trial of RVX-208 in CAD

Avexa reports results from phase III study of apricitabine in drug-resistant HIV

Cara Therapeutics reports results of phase II CR-845 trial in acute postoperative pain

Abbott reports results from fourth quarter of 2009

Lilly's Gemzar approved in Japan for additional indication of breast cancer

Inovio Biomedica reports on phase I trial of its cervical cancer vaccine VGX-3100

Nabi completes milestone in sale of PentaStaph S. aureus vaccine to GSK

Dynavax Technologies begins phase III trial of Heplisav hepatitis B vaccine for adults

Novavax discontinues negotiations with Rovi to develop influenza vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...